Enhanced anti-angiogenic effect of E7820 in combination with erlotinib in epidermal growth factor receptor–tyrosine kinase inhibitor-resistant non-small-cell lung cancer xenograft models

Most non-small-cell lung cancers (NSCLCs) harboring activating mutations in the epidermal growth factor receptor (EGFR) are initially responsive to EGFR tyrosine kinase inhibitors (EGFR-TKIs); however, they invariably develop resistance to these drugs. E7820 is an angiogenesis inhibitor that decreas...

Descripción completa

Detalles Bibliográficos
Autores principales: Ito, Ken, Semba, Taro, Uenaka, Toshimitsu, Wakabayashi, Toshiaki, Asada, Makoto, Funahashi, Yasuhiro
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Blackwell Publishing Ltd 2014
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4317852/
https://www.ncbi.nlm.nih.gov/pubmed/24841832
http://dx.doi.org/10.1111/cas.12450

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4317852/
https://www.ncbi.nlm.nih.gov/pubmed/24841832
http://dx.doi.org/10.1111/cas.12450

Ejemplares similares